Want to see SE:ANNX full AI Analyst Report?
Top Page
Annexin Pharmaceuticals AB
(ANNX)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr13.50
▼(-32.16% Downside)
Action:Reiterated
Date:01/30/26
Overall score is driven primarily by weak financial performance (no revenue, heavy losses, and rising cash burn with declining equity), complemented by bearish technicals (price below major moving averages and negative MACD). Valuation is difficult to support with a negative P/E and no dividend yield data.
Positive Factors
Debt-free balance sheet
Zero reported debt materially reduces bankruptcy and interest-rate risk for a clinical-stage biotech. This structural strength preserves flexibility to fund trials via equity or partnerships without debt covenants, supporting longer-term project continuity and strategic optionality.
Negative Factors
No commercial revenue (2020–2024)
Absent any product revenue, the company is fully reliant on external financing or partnerships to fund operations. Over the medium term this increases dilution and execution risk, as sustainable operations hinge on uncertain clinical success or non-dilutive funding events.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported debt materially reduces bankruptcy and interest-rate risk for a clinical-stage biotech. This structural strength preserves flexibility to fund trials via equity or partnerships without debt covenants, supporting longer-term project continuity and strategic optionality.
Read all positive factors
Annexin Pharmaceuticals AB (ANNX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr112.46M
Dividend YieldN/A
Average Volume (3M)1.96K
Price to Earnings (P/E)―
Beta (1Y)0.90
Revenue GrowthN/A
EPS Growth42.21%
CountrySE
Employees4
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.41
Shares Outstanding8,718,182
10 Day Avg. Volume1,714
30 Day Avg. Volume1,964
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.25
Price to Sales (P/S)0.00
P/FCF Ratio-3.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr76.90M
Annexin Pharmaceuticals AB Business Overview & Revenue Model
Company Description
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects a...
How the Company Makes Money
Annexin Pharmaceuticals is a clinical-stage biotechnology company; specific recurring product sales are not publicly indicated in the provided context, so its commercial revenue model is not established. null...
Annexin Pharmaceuticals AB Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
38
Negative
Cash Flow
8
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -48.00K | -48.00K | -193.00K | -193.00K | -193.00K | -192.00K |
| EBITDA | -38.90M | -36.84M | -50.20M | -43.86M | -40.72M | -50.28M |
| Net Income | -39.44M | -36.89M | -50.25M | -44.05M | -40.73M | -52.14M |
Balance Sheet | ||||||
| Total Assets | 19.98M | 30.16M | 19.04M | 26.76M | 36.68M | 52.79M |
| Cash, Cash Equivalents and Short-Term Investments | 17.07M | 27.39M | 16.34M | 21.41M | 31.11M | 49.48M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 5.56M | 5.22M | 5.32M | 7.95M | 6.53M | 6.06M |
| Stockholders Equity | 14.42M | 24.93M | 13.71M | 18.81M | 30.15M | 46.73M |
Cash Flow | ||||||
| Free Cash Flow | -29.20M | -37.05M | -50.23M | -43.40M | -41.16M | -45.02M |
| Operating Cash Flow | -29.07M | -36.92M | -50.23M | -43.40M | -41.16M | -45.02M |
| Investing Cash Flow | -129.00K | -129.00K | 0.00 | 96.00K | -260.00K | 0.00 |
| Financing Cash Flow | 10.97K | 48.11M | 45.15M | 33.61M | 23.06M | 76.37M |
Annexin Pharmaceuticals AB Peers Comparison
UnderperformOutperform
Sector (55)
SE:ANNX
Annexin Pharmaceuticals AB
13.20
-15.37
-53.79%
SE:MVIR
Medivir AB
1.66
-0.29
-15.08%
DE:5IU
Isofol Medical AB
0.06
>-0.01
-1.59%
DE:6IRA
IRLAB Therapeutics AB Class A
0.14
-0.12
-46.27%
DE:99Z
Modus Therapeutics Holding AB
0.03
-0.12
-83.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.